BioNTech (NASDAQ:BNTX) Stock Price Up 3.9% – Should You Buy?

Shares of BioNTech SE (NASDAQ:BNTX) shot up 3.9% during trading on Monday . The stock traded as high as $99.18 and last traded at $96.43. 221,226 shares changed hands during trading, a decline of 76% from the average session volume of 929,876 shares. The stock had previously closed at $92.77.

Analyst Ratings Changes

Several equities analysts have issued reports on BNTX shares. Citigroup restated a “buy” rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Morgan Stanley cut their price objective on BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. BMO Capital Markets raised their price objective on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a “buy” rating and set a $134.00 price objective (down previously from $145.00) on shares of BioNTech in a research note on Wednesday, May 14th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus target price of $142.08.

BioNTech Stock Up 4.7%

The company has a 50-day moving average of $97.41 and a two-hundred day moving average of $108.81. The company has a market capitalization of $23.36 billion, a P/E ratio of -46.27 and a beta of 1.35. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.90 earnings per share. On average, research analysts predict that BioNTech SE will post -3.88 EPS for the current year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. Daiwa Securities Group Inc. grew its stake in BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company’s stock worth $221,000 after purchasing an additional 128 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after buying an additional 150 shares in the last quarter. Probity Advisors Inc. raised its holdings in shares of BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company’s stock worth $224,000 after acquiring an additional 154 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of BioNTech by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock valued at $227,000 after purchasing an additional 209 shares during the last quarter. Finally, Midwest Professional Planners LTD. raised its holdings in BioNTech by 5.8% in the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company’s stock valued at $462,000 after acquiring an additional 222 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.